Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis.

Clicks: 324
ID: 63781
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #12 of 85 articles by views in Annals of hematology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Ruxolitinib is the only commercially available JAK1/2 inhibitor approved for the treatment of myelofibrosis-related splenomegaly and symptoms. During treatment, as rare conditions, leukocytosis and/or thrombocytosis could develop and the management of these situations is not well established. We report here 53 myelofibrosis patients that received a combination of hydroxyurea and ruxolitinib because of uncontrolled myeloproliferation. Both drugs were administered outside clinical trials. At 48 weeks, a significant reduction in leucocyte and platelet counts was observed (p = 0.02 and p = 0.04, respectively). Additionally, the spleen volume decreased from a median value of 10 cm below the left costal margin (range, 0-10) to 6 cm (range, 0-15). The rate of spleen response increased from 14% at the start of the combination to 45% after 48 weeks. The safety profile of the combination was consistent with that observed with ruxolitinib single agent. These data require further confirmation in large cohorts of patients prospectively assessed.
Reference Key
breccia2019efficacyannals Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Breccia, Massimo;Luciano, Luigiana;Pugliese, Novella;Rossi, Elena;Tiribelli, Mario;Scalzulli, Emilia;Bonifacio, Massimiliano;Martino, Bruno;Latagliata, Roberto;Benevolo, Giulia;Caocci, Giovanni;Binotto, Gianni;Martinelli, Vincenzo;Cavo, Michele;Pane, Fabrizio;De Stefano, Valerio;Foà, Robin;Palandri, Francesca;
Journal Annals of hematology
Year 2019
DOI
10.1007/s00277-019-03727-6
URL
Keywords
efficacy myelofibrosis ruxolitinib hydroxyurea

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.